Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited researches, develops, manufactures, and sells Chinese patent and Western medicines, chemical raw materials, natural and biological medicines, and intermediates of chemical raw materials. The company operates through Great Southern TCM, Great Commerce, Great Health, and Other segments. It is also involved in the wholesale, retail, sale, … Read more
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Total Liabilities
Latest total liabilities as of June 2025: €42.61 Billion EUR
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has total liabilities worth €42.61 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Total Liabilities Trend (2013–2024)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Total Liabilities
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
VALIF
PINK:VALIF
|
USA | $35.11 Billion |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
China | CN¥2.57 Billion |
|
Atlas Corp
NASDAQ:ATCOL
|
USA | $11.96 Billion |
|
Inner Mongolia Yitai Coal Co Ltd
SHG:900948
|
China | $39.00 Billion |
|
CITIC Pacific Special Steel Group Co Ltd
SHE:000708
|
China | CN¥66.75 Billion |
|
Grandblue Environment Co Ltd
SHG:600323
|
China | CN¥44.50 Billion |
|
Jiangsu Boqian New Materials Stock Co Ltd
SHG:605376
|
China | CN¥333.09 Million |
|
Under Armour Inc A
NYSE:UAA
|
USA | $3.19 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2024)
The table below shows the annual total liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €43.91 Billion | +4.78% |
| 2023-12-31 | €41.91 Billion | +2.15% |
| 2022-12-31 | €41.03 Billion | +17.93% |
| 2021-12-31 | €34.79 Billion | +10.26% |
| 2020-12-31 | €31.55 Billion | +2.11% |
| 2019-12-31 | €30.90 Billion | +9.05% |
| 2018-12-31 | €28.34 Billion | +213.08% |
| 2017-12-31 | €9.05 Billion | +9.80% |
| 2016-12-31 | €8.24 Billion | +14.70% |
| 2015-12-31 | €7.19 Billion | +13.27% |
| 2014-12-31 | €6.34 Billion | +21.39% |
| 2013-12-31 | €5.23 Billion | -- |